Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H25N3O2S |
Molecular Weight | 335.464 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC1=CNC2=CC=C(CS(=O)(=O)N3CCCC3)C=C12
InChI
InChIKey=WKEMJKQOLOHJLZ-UHFFFAOYSA-N
InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
Molecular Formula | C17H25N3O2S |
Molecular Weight | 335.464 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is marketed under the trade name Axert. Almotriptan is used for treating acute migraine headaches with or without aura (eg, dark spots, flashing lights, wavy lines). Almotriptan binds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F receptors.
Almotriptan has weak affinity for 5-HT1A and 5-HT7 receptors, but has no significant
affinity or pharmacological activity at 5-HT2, 5-HT3, 5-HT4, 5-HT6; alpha or beta
adrenergic; adenosine (A1, A2); angiotensin (AT1, AT2); dopamine (D1, D2);
endothelin (ETA, ETB); or tachykinin (NK1, NK2, NK3) binding sites.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1898 |
|||
Target ID: CHEMBL1983 |
|||
Target ID: CHEMBL1805 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AXERT Approved UseAlmotriptan tablets, USP are a 5HT1B/1D receptor agonist (triptan) indicated for: •Acute treatment of migraine attacks in adults with a history of migraine with or without aura (1.1) •Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more (1.1) Important Limitations: •Use only after a clear diagnosis of migraine has been established (1.2) •In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms was not established (1.2) •Not intended for the prophylactic therapy of migraine (1.2) •Not indicated for the treatment of cluster headache (1.2) 1.1 Acute Treatment of Migraine Attacks Adults Almotriptan tablets, USP are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura. Adolescents Age 12 to 17 Years Almotriptan tablets are indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). 1.2 Important Limitations Almotriptan tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with almotriptan tablets, the diagnosis of migraine should be reconsidered before almotriptan tablets are administered to treat any subsequent attacks. In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. Almotriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine [see Contraindications (4.7) Launch Date9.8919357E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
52.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12723463 |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALMOTRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
312 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12723463 |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALMOTRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12723463 |
12.5 mg single, oral dose: 12.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALMOTRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.5 h |
unknown, oral |
ALMOTRIPTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
65% |
unknown, oral |
ALMOTRIPTAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mg single, intravenous Dose: 3 mg Route: intravenous Route: single Dose: 3 mg Sources: |
healthy, 19-33 years n = 24 Health Status: healthy Age Group: 19-33 years Sex: M Population Size: 24 Sources: |
|
10 mg single, subcutaneous Highest studied dose Dose: 10 mg Route: subcutaneous Route: single Dose: 10 mg Sources: |
unhealthy, 42 years (range: 18-72 years) n = 31 Health Status: unhealthy Condition: acute migraine Age Group: 42 years (range: 18-72 years) Sex: M+F Population Size: 31 Sources: |
|
12.5 mg multiple, oral Recommended Dose: 12.5 mg Route: oral Route: multiple Dose: 12.5 mg Sources: |
unhealthy, 42 years (range: 18-72 years) n = 582 Health Status: unhealthy Condition: acute migraine Age Group: 42 years (range: 18-72 years) Sex: M+F Population Size: 582 Sources: |
Disc. AE: Chest pain, Electrocardiogram QTc interval prolonged... AEs leading to discontinuation/dose reduction: Chest pain (0.9%) Sources: Electrocardiogram QTc interval prolonged (0.7%) |
100 mg multiple, oral Highest studied dose Dose: 100 mg Route: oral Route: multiple Dose: 100 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
|
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: |
healthy, adult n = 6 Health Status: healthy Age Group: adult Population Size: 6 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Electrocardiogram QTc interval prolonged | 0.7% Disc. AE |
12.5 mg multiple, oral Recommended Dose: 12.5 mg Route: oral Route: multiple Dose: 12.5 mg Sources: |
unhealthy, 42 years (range: 18-72 years) n = 582 Health Status: unhealthy Condition: acute migraine Age Group: 42 years (range: 18-72 years) Sex: M+F Population Size: 582 Sources: |
Chest pain | 0.9% Disc. AE |
12.5 mg multiple, oral Recommended Dose: 12.5 mg Route: oral Route: multiple Dose: 12.5 mg Sources: |
unhealthy, 42 years (range: 18-72 years) n = 582 Health Status: unhealthy Condition: acute migraine Age Group: 42 years (range: 18-72 years) Sex: M+F Population Size: 582 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 49.0 |
no | |||
Page: 49.0 |
no | |||
Page: 49.0 |
no | |||
Page: 49.0 |
no | |||
Page: 49.0 |
no | |||
Page: 49.0 |
no | |||
Page: 49.0 |
no | |||
Page: 49.0 |
no | |||
Page: 49.0 |
weak [Ki 87 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 27.0 |
yes | |||
Page: 27.0 |
yes | |||
Page: 27.0 |
yes | |||
Page: 27.0 |
yes | |||
Page: 27, 49 |
yes | |||
Page: 27.0 |
yes | |||
Page: 27.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Comparative aspects of triptans in treating migraine. | 2001 |
|
Almotriptan: pharmacological differences and clinical results. | 2001 |
|
Rizatriptan: an update of its use in the management of migraine. | 2002 |
|
Spotlight on almotriptan in migraine. | 2002 |
|
Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. | 2002 Apr |
|
Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. | 2002 Dec |
|
How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. | 2002 Feb |
|
Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms. | 2002 Feb |
|
Health outcomes evaluations: estimating the impact of almotriptan in managed care settings. | 2002 Feb |
|
Migraine: diagnosis, management, and new treatment options. | 2002 Feb |
|
A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. | 2002 Jan |
|
Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. | 2002 Jan |
|
Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. | 2002 Jan |
|
Almotriptan increases pain-free status in patients with acute migraine treated in placebo-controlled clinical trials. | 2002 Jan |
|
Gateways to clinical trials. | 2002 Jan-Feb |
|
Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. | 2002 Jul |
|
Mechanisms of action of the 5-HT1B/1D receptor agonists. | 2002 Jul |
|
Cardiovascular effect of almotriptan in treated hypertensive patients. | 2002 Mar |
|
Efficacy and safety of almotriptan malate for migraine. | 2002 Nov 15 |
|
Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. | 2002 Oct |
|
Current perspectives on effective migraine treatments: are small clinical differences important for patients? | 2003 |
|
Almotriptan: an effective and well-tolerated treatment for migraine pain. | 2003 |
|
Newer formulations of the triptans: advances in migraine management. | 2003 |
|
Gateways to clinical trials. | 2003 Dec |
|
Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. | 2003 Jan-Feb |
|
[Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study]. | 2003 Jan-Feb |
|
A review of the clinical efficacy and tolerability of almotriptan in acute migraine. | 2003 Jul |
|
Almotriptan versus rizatriptan in patients with migraine in Spain. | 2003 Jul-Aug |
|
Safety profile of the triptans. | 2003 Mar |
|
A case of carotidynia with response to almotriptan. | 2003 Mar |
|
Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. | 2003 Nov |
|
Migraine: diagnosis and management. | 2003 Sep-Oct |
|
Clinical benefits of early triptan therapy for migraine. | 2004 |
|
Clinical profile and practice experience of almotriptan. | 2004 |
|
What do patients want from acute migraine treatment? | 2004 |
|
Migraine pathophysiology and its clinical implications. | 2004 |
|
Almotriptan improves response rates when treatment is within 1 hour of migraine onset. | 2004 Apr |
|
Triptans and chest symptoms: the role of pulmonary vasoconstriction. | 2004 Apr |
|
Meta-analysis of oral triptans. | 2004 Aug |
|
Evaluating triptan usage. | 2004 Feb |
|
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. | 2004 Feb 26 |
|
Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. | 2004 Jul |
|
Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. | 2004 Jul-Aug |
|
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. | 2004 Jun |
|
Cost considerations of acute migraine treatment. | 2004 Mar |
|
A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. | 2004 May-Jun |
|
Evaluating triptan usage: a rebuttal. | 2004 Oct |
|
Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. | 2004 Oct |
|
TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. | 2004 Sep |
|
Correlation between lipophilicity and triptan outcomes. | 2005 Jan |
Patents
Sample Use Guides
Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single
dose; may repeat after 2 hours if headache returns; benefit of second dose
in patients who have failed to respond to first dose has not been
established; maximum daily dose 25 mg
Patients with hepatic or severe renal impairment: 6.25 mg starting dose;
maximum daily dose 12.5 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11737005
In vitro Almotriptan showed selectivity of action for migraine-related human arteries (i.e. contractile EC(50) of 30 and 700 nm for meningeal and temporal arteries, respectively), whereas the effect on arteries supplying blood to the brain was lower.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:12:53 UTC 2023
by
admin
on
Wed Jul 05 23:12:53 UTC 2023
|
Record UNII |
1O4XL5SN61
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02CC05
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
||
|
NDF-RT |
N0000175764
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
||
|
NCI_THESAURUS |
C47794
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
||
|
LIVERTOX |
27
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
||
|
NDF-RT |
N0000175763
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
||
|
NDF-RT |
N0000175765
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
||
|
WHO-ATC |
N02CC05
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
154323-57-6
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
128
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
CHEMBL1505
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
M1568
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB00918
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
7110
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
279645
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | RxNorm | ||
|
C409045
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
DTXSID5044289
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
ALMOTRIPTAN
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
1O4XL5SN61
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
JJ-24
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
C65224
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
SUB05350MIG
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
1O4XL5SN61
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
760092
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
7463
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
Almotriptan
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
123606
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
520985
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY | |||
|
100000087462
Created by
admin on Wed Jul 05 23:12:53 UTC 2023 , Edited by admin on Wed Jul 05 23:12:53 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
EXCRETED UNCHANGED |
Approximately 3% of the administered dose is excreted via feces, both unchanged and metabolized.
FECAL
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||